Meeting
2016 ASCO Annual Meeting
MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.
Authors
Beverly Long
Mayo Clinic, Rochester, MN
Beverly Long , Xiaonan Hou , Marc Becker , Jamison VanBlaricom , Evans Bradley , Andrea Elisabeth Wahner Hendrickson , Ann L. Oberg , Matthew John Maurer , Ethan Heinzen , John Kelly Camoriano , Gerardo Colon-Otero , Jill K. Burton , Kimberly Kalli , Nathan R. Foster , Paul Haluska , Saravut John Weroha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02312245
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS5609)
DOI
10.1200/JCO.2016.34.15_suppl.TPS5609
Abstract #
TPS5609
Poster Bd #
426a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2016 ASCO Annual Meeting
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase 2 study.
First Author: Ursula A. Matulonis
Poster
2022 ASCO Annual Meeting
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.
First Author: Gordon Taylor Moffat
Poster
2022 ASCO Annual Meeting
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Thomas J. Herzog